Literature DB >> 36268247

Highly variable biodistribution of 68Ga labeled somatostatin analogues 68Ga-DOTA-NOC and 68Ga-DOTA-TATE in neuroendocrine tumors: clinical implications for somatostatin receptor directed PET/CT.

Monica Cheng1, Mark Tann1.   

Abstract

Background: Somatostatin receptor (SSTR)-targeted positron emission tomography/computed tomography (PET/CT) imaging has risen to the forefront for neuroendocrine tumor (NET) detection and management, yet the variability of significant uptake variability (SUV) as a semiquantitative measure of disease detection and tumor response to treatment has not been fully explored.
Methods: We assess the reproducibility and interscan variability of SUV metrics of normal tissue and NET in serial 68Ga-DOTA-NOC and 68Ga-DOTA-TATE PET imaging to clinically monitor disease state. Eighty-one patients were enrolled in this retrospective study.
Results: Both primary and metastatic hepatic lesions demonstrated SUV (SUVmean 16.5±8.0). The median SUVmean was 16 for the spleen, 9.7 for the pituitary, 12.6 for the adrenal glands, and 4.8 for the liver. The normal pituitary gland demonstrates focal homogenous uptake with SUVmax range of 4.5-23. The adrenal gland showed uptake with SUVmax range of 4.1-29.4, which is more than two times greater than liver uptake (SUVmean range, 2.3-12.4). Highest physiological uptake seen in the spleen (average SUVmean of 17.3, range of 5.4-34.4). Conclusions: The highly variable nature of regional SUVmean and SUVmax in both physiologic tissue and lesions suggests the need for incorporation of more reliable quantitative measures for clinical decision making. 2022 Hepatobiliary Surgery and Nutrition. All rights reserved.

Entities:  

Keywords:  68Ga-DOTA PET imaging; Neuroendocrine tumors (NETs); gastrointestinal tract; liver; pancreas; somatostatin receptors (SSTRs); targeted therapy

Year:  2022        PMID: 36268247      PMCID: PMC9577978          DOI: 10.21037/hbsn-21-554

Source DB:  PubMed          Journal:  Hepatobiliary Surg Nutr        ISSN: 2304-3881            Impact factor:   8.265


  36 in total

1.  The tumour sink effect on the biodistribution of 68Ga-DOTA-octreotate: implications for peptide receptor radionuclide therapy.

Authors:  Jean-Mathieu Beauregard; Michael S Hofman; Grace Kong; Rodney J Hicks
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-09-20       Impact factor: 9.236

2.  Impact of Tumor Burden on Quantitative [68Ga] DOTATOC Biodistribution.

Authors:  Rudolf A Werner; Heribert Hänscheid; Jeffrey P Leal; Mehrbod S Javadi; Takahiro Higuchi; Martin A Lodge; Andreas K Buck; Martin G Pomper; Constantin Lapa; Steven P Rowe
Journal:  Mol Imaging Biol       Date:  2019-08       Impact factor: 3.488

3.  Radioguided surgery with 68Ga-DOTATATE for patients with neuroendocrine tumors.

Authors:  Valentina Ambrosini; Stefano Fanti
Journal:  Hepatobiliary Surg Nutr       Date:  2020-02       Impact factor: 7.293

4.  Semiquantitative analysis and characterization of physiological biodistribution of (68)Ga-DOTA-TATE PET/CT.

Authors:  Jolanta Kunikowska; Leszek Królicki; Dariusz Pawlak; Imene Zerizer; Renata Mikołajczak
Journal:  Clin Nucl Med       Date:  2012-11       Impact factor: 7.794

5.  Comparison of (68)Ga-DOTA-Tyr(3)-octreotide and (18)F-fluoro-L-dihydroxyphenylalanine positron emission tomography in neuroendocrine tumor patients.

Authors:  D Putzer; M Gabriel; D Kendler; B Henninger; M Knoflach; A Kroiss; E Vonguggenberg; B Warwitz; I J Virgolini
Journal:  Q J Nucl Med Mol Imaging       Date:  2010-02       Impact factor: 2.346

Review 6.  Neuroendocrine neoplasia of the gastrointestinal tract revisited: towards precision medicine.

Authors:  Guido Rindi; Bertram Wiedenmann
Journal:  Nat Rev Endocrinol       Date:  2020-08-24       Impact factor: 43.330

Review 7.  Peptide Receptor Radionuclide Therapy of Neuroendocrine Tumors.

Authors:  Sandip Basu; Rahul V Parghane; Sudipta Chakrabarty
Journal:  Semin Nucl Med       Date:  2020-07-03       Impact factor: 4.446

8.  Spectrum of 68Ga-DOTA TATE Uptake in Patients With Neuroendocrine Tumors.

Authors:  Farshad Moradi; Mehran Jamali; Amir Barkhodari; Bernadette Schneider; Frederick Chin; Andrew Quon; Erik S Mittra; Andrei Iagaru
Journal:  Clin Nucl Med       Date:  2016-06       Impact factor: 7.794

Review 9.  68Gallium- and 90Yttrium-/ 177Lutetium: "theranostic twins" for diagnosis and treatment of NETs.

Authors:  Rudolf A Werner; Christina Bluemel; Martin S Allen-Auerbach; Takahiro Higuchi; Ken Herrmann
Journal:  Ann Nucl Med       Date:  2014-08-20       Impact factor: 2.668

10.  Role of C11-FDG dual-tracer PET-CT scan in metastatic screening of hepatocellular carcinoma-a cost-effectiveness analysis.

Authors:  Kevin K W Chu; Albert C Y Chan; Ka Wing Ma; Wong Hoi She; Wing Chiu Dai; Kenneth S H Chok; Tan To Cheung; Chung Mau Lo
Journal:  Hepatobiliary Surg Nutr       Date:  2021-06       Impact factor: 7.293

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.